MoonLake Immunotherapeutics (MLTX) Shares Outstanding (2020 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Shares Outstanding (Entity) of $72.1 million for Q1 2026, up 12.35% year-over-year from $64.2 million in Q1 2025, and up 1.07% quarter-over-quarter from $71.4 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Shares Outstanding (2020 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $72.1 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 12.35% year-over-year to $72.1 million; the TTM figure through Mar 2026 stood at $72.1 million (up 12.35% YoY), while the FY2025 annual figure was $71.4 million, up 11.66% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $72.1 million, up from $71.4 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $72.1 million in Q1 2026, with the low at $5.0 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $63.9 million (2024), against an average of $52.5 million.
- Peak annual rise in Shares Outstanding (Entity) reached 1444.63% in 2022, while the deepest fall reached 56.4% in 2022.
- MoonLake Immunotherapeutics' Shares Outstanding (Entity) stood at $29.4 million in 2022, then soared by 67.3% to $49.1 million in 2023, then jumped by 30.12% to $63.9 million in 2024, then climbed by 11.66% to $71.4 million in 2025, then rose by 1.07% to $72.1 million in 2026.
- Business Quant data shows MLTX's Shares Outstanding (Entity) at $72.1 million in Q1 2026, $71.4 million in Q4 2025, and $64.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 73.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.92 Mn |
| Mar 31, 2026 | 71.27 Mn |
| Dec 31, 2025 | 64.46 Mn |
| Sep 30, 2025 | 63.37 Mn |
| Jun 30, 2025 | 63.28 Mn |
| Mar 31, 2025 | 63.23 Mn |
| Dec 31, 2024 | 62.87 Mn |
| Sep 30, 2024 | 62.90 Mn |
| Jun 30, 2024 | 62.87 Mn |
| Mar 31, 2024 | 62.64 Mn |
| Dec 31, 2023 | 49.12 Mn |
| Sep 30, 2023 | 53.52 Mn |
| Jun 30, 2023 | 43.72 Mn |
| Mar 31, 2023 | 39.06 Mn |
| Dec 31, 2022 | 29.36 Mn |
| Sep 30, 2022 | 36.93 Mn |
| Jun 30, 2022 | 35.20 Mn |
| Mar 31, 2022 | 5.01 Mn |
| Dec 31, 2021 | 11.93 Mn |
| Sep 30, 2021 | 2.39 Mn |